Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Analysis of a Swiss cohort

Détails

ID Serval
serval:BIB_BEAF6B43FB6A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Analysis of a Swiss cohort
Périodique
Dermatology
Auteur(s)
Simon  D., Lubbe  J., Wuthrich  B., Wiesner  A., Weber  M. M., Laffitte  E., Anliker  M. D., Schoni  M. H., Braathen  L. R., Schmid-Grendelmeier  P., Gilgen Bobalj  N., Schneider  D.
ISSN
1018-8665 (Print)
Statut éditorial
Publié
Date de publication
2006
Volume
213
Numéro
4
Pages
313-8
Notes
Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Résumé
BACKGROUND: Controlled studies established the efficacy and good tolerability of pimecrolimus cream 1% for the treatment of atopic dermatitis but they may not reflect real-life use. OBJECTIVE: To evaluate the efficacy, tolerability and cosmetic acceptance of a pimecrolimus-based regimen in daily practice in Switzerland. METHODS: This was a 6-month, open-label, multicentre study in 109 patients (55% > or = 18 years) with atopic dermatitis. Pimecrolimus cream 1% was incorporated into patients' standard treatment protocols. RESULTS: The pimecrolimus-based treatment was well tolerated and produced disease improvement in 65.7% of patients. It was particularly effective on the face (improvement rate: 75.0%). Mean pimecrolimus consumption decreased from 6.4 g/day (months 1-3) to 4.0 g/day (months 3-6) as disease improved. Most patients (74.1%) rated their disease control as 'complete' or 'good' and 90% were highly satisfied with the cream formulation. CONCLUSION: The use of a pimecrolimus-based regimen in everyday practice was effective, well tolerated and well accepted by patients.
Mots-clé
Administration, Cutaneous Adolescent Adult Aged Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use Calcineurin/*antagonists & inhibitors Child Child, Preschool Cohort Studies Dermatitis, Atopic/*drug therapy Facial Dermatoses/drug therapy Female Follow-Up Studies Humans Infant Male Middle Aged Ointments Patient Satisfaction Peptidylprolyl Isomerase/*antagonists & inhibitors Safety Tacrolimus/administration & dosage/*analogs & derivatives/therapeutic use Treatment Outcome
Pubmed
Web of science
Création de la notice
25/01/2008 17:41
Dernière modification de la notice
20/08/2019 16:32
Données d'usage